Brigitte Sola

High sensitivity of protoplasmic cortical astroglia to focal ischemia.

Dysfunction of the Fas apoptotic signaling pathway in persistent polyclonal B-cell lymphocytosis.

Relevance of cyclin D1 level in the pathogenesis of multiple myeloma.

The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines.

The enigmatic role of cyclin D1 in multiple myeloma.

4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.

Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma.

Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation.

Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma.

Antiestrogenic therapies in solid cancers and multiple myeloma.

Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma.

Alternative cyclin D1 forms a and b have different biological functions in the cell cycle of B lymphocytes.

Estrogenic or antiestrogenic therapies for multiple myeloma?

Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.

Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells.

Anti-tumor necrosis factor-alpha (TNF-alpha) treatment strategies in Crohn's disease.

Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies.

Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model.

Reduction of cell proliferation and potentiation of Fas-induced apoptosis by the selective kappa-opioid receptor agonist U50 488 in the multiple myeloma LP-1 cells.

Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Cyclin D1 regulates p27(Kip1) stability in B cells.

Cyclin D1 inhibits mitochondrial activity in B cells.

4-Hydroxy-tamoxifen-loaded liposomes have potent anti-myeloma activity.